UNSPSC 51282807: Telithromycin

This classification denotes a macrolide antibiotic with the molecular formula C43H65N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KI8H7H19WL, chemically known as erythromycin, 3-de((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-o-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1h-imidazol-1-yl)butyl)imino))- but generally known as telithromycin, which bears US NIH Compound Identifier 3002190.

UNSPSC 51282807 Telithromycin is a Commodity code for a specific antibiotic pharmaceutical product, but recent state and local procurement activity under this code shows little direct alignment with telithromycin purchases. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement — including warehouse supply contracts for other antibiotics and opioid-reversal medications serving public health and emergency response missions across state health departments and county governments.

Recent activity centers on Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392), covering supply of Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets with a 12-month initial term and two renewal options. Seminole County, Florida posted an IFB on June 30, 2026 (IFB 60459723LAS) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries required and a response deadline of July 26, 2023. The code shows limited recent solicitation volume specifically for telithromycin; the opportunities present suggest that state and local procurement offices may use this code to tag pharmaceutical supply agreements more broadly, or the code sees infrequent direct use. Firms pursuing pharmaceutical supply to state health departments and county public health bodies should monitor whether opportunities under this code represent steady demand or occasional tagging of multi-drug warehouse contracts.